August 2024 A recent study conducted in the United States showed that when unprocessed red meat and processed meat consumption was reduced by 30% over a period of 10 years, it led to significant decreases in chronic diseases and death. Unprocessed red meats: meats such as beef, pork, and lamb ...
The most common question we receive in Support Services from folks who have been diagnosed with cancer is “why did I get cancer? I did everything right”. The truth is, unless your cancer has been directly associated with genetics, you may never find the answer to this question. Cancer risk ...
June 2024 Early clinical results have shown that locally advanced (stage III) mismatch repair deficient (dMMR) rectal cancers can respond very well to immunotherapy alone, therefore allowing patients to avoid treatment with chemotherapy, radiation, or surgery. The long-term impact of immunotherapy treatment on this patient population, however, is unknown. A ...
June 2024 A phase II study presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting aimed to investigate whether the immunotherapy agent pembrolizumab given before surgery may improve outcomes in certain patients with stage II or III dMMR/MSI-H colorectal cancer (CRC). Immunotherapy: a class of drugs ...
We are excited to announce the publication of our latest manuscript, in Current Oncology, detailing the experiences of early-onset colorectal cancer patients and caregivers in Canada as part of our Never Too Young Program. This study provides valuable insights into gaps in care and how to address them. You can ...
We are pleased to announce the publication of our manuscript, "Understanding Colorectal Cancer Patient Experiences with Family Practitioners in Canada," in Current Oncology. This study explores CRC patient experiences with family practitioners during and after diagnosis, highlighting gaps and opportunities to improve patient-centered care and outcomes across Canada. You can ...
What is survivorship? Survivorship is a term used to describe people living with Cancer, in treatment for Cancer, who have no evidence of disease after cancer treatment, people receiving treatment for a longer period to reduce risk of Cancer returning, and people with advanced Cancer. The word “survivorship” may not ...
PERIOP-06 is a phase II study that will assess the efficacy of a medicinal product known as a Site Specific Immunomodulator (SSI) in patients who have planned to undergo surgery to remove colorectal cancer that has spread to the liver (metastases). The SSI under investigation, called QBECO, is designed to ...
This phase I/II clinical study will evaluate the ability of a new type of vaccine, Nous-209, in combination with another drug, pembrolizumab (also called Keytruda), to provide a beneficial effect as a treatment for certain types of colorectal cancer (CRC). About Nous-209 and Pembrolizumab Nous-209 is a genetic vaccine that ...
May 2024 According to a recent study published in Microbiology Spectrum, specific microbiome “signatures” were associated with KRAS mutations in patients with colorectal cancer (CRC). These signatures include unique microbiome characteristics such as the presence of specific bacteria, which may serve as a biomarker or indicator for the presence of ...
1 Westmount Square, Suite 1630
Westmount, QC H3Z 2P9
Canada
info@colorectalcancercanada.com
© Colorectal Cancer Canada All rights reserved
Charitable registration number 86657 2423 RR0001
